NSCLC subtype: adenocarcinoma, squamous or other histology
This point is checked because it can change suitability, timing, safety or the next document request.
File-based coordination for non-small cell lung cancer, with attention to histology, stage, biomarkers, previous systemic therapy and the clinical context in which Cuban biotechnology options may be discussed.

The review begins by separating confirmed NSCLC from small-cell disease, then organizing biomarker status, staging images and treatment history. This avoids presenting CIMAvax-EGF or Vaxira as a generic option and keeps the discussion physician-led.
Key medical markers
Performance, symptoms, urgent risks and treatment tolerance are documented.
The record must show what has already been tried and how the disease responded.
The case is prepared so the physician can answer a clear medical question.

The page is not a generic brochure. Each diagnosis is organized around the clinical details that actually affect specialist review.
This point is checked because it can change suitability, timing, safety or the next document request.
This point is checked because it can change suitability, timing, safety or the next document request.
This point is checked because it can change suitability, timing, safety or the next document request.
This point is checked because it can change suitability, timing, safety or the next document request.
The purpose is to provide a documented, physician-led evaluation route without advertising a single treatment option as a universal solution.
Surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy and supportive care remain physician-led according to stage and prior response.
CIMAvax-EGF and Vaxira are placed only as clinical discussion points for selected NSCLC contexts after specialist review, never as guaranteed treatment.
Cuba Health Assist organizes the medical file, communication and logistics; the treating physicians determine suitability and medical route.


Incomplete files lead to avoidable delay and unrealistic expectations. These are the usual starting documents; the physician may request more.
Primary diagnosis, biopsy or surgical pathology, immunohistochemistry and molecular profile when available.
Recent CT, MRI, PET/CT, ultrasound or other staging images with written radiology reports.
Surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy and response/side-effect details.
CBC, liver/kidney function, coagulation and tumor markers requested by the medical team.
Performance status, weight loss, pain, symptoms, nutrition, active infection and medication list.
Oncology consultation notes, discharge summaries and the current treatment recommendation.

The process is designed to protect clinical clarity. The patient understands what is being reviewed, what is missing and what the physician can or cannot evaluate.
Reports, imaging, photos and medical history are uploaded through the application flow.
The coordination team checks readability, translations, dates and missing items.
The case is prepared for the relevant physician review according to diagnosis and urgency.
The patient receives a written next-step explanation before committing to travel or treatment.
No. It explains how the file is prepared. Suitability can only be determined after specialist review of the complete current medical record.
Photos and summaries help, but they are not enough for most cases. Written reports, dates, imaging and laboratory results are usually required.
No. Treatment, route, timing and follow-up must be confirmed by licensed physicians after reviewing the file.
Cuba Health Assist coordinates the file, communication, translations where needed, document organization and next-step logistics.
A coordinator will request the missing reports, images or laboratory results before forwarding the case for a final review.
A coordinator will organize the information and guide the next step according to specialist review.